Western medicine is a field of medicine that treats diseases that are related to inflammation, such as the common cold and the flu.
The drug company Pfizer has its own brand of Sovaldi, which is being developed by a UK company, GSK.
The company has already spent more than $1bn to develop Sovaldi.
But it is unclear whether it is likely to be the first to market.
A survey by the New York Times found that the average cost of a prescription drug for the US was about $100.
But the price of Sovadix, the next-highest-priced drug on the list, was $130.
The Times said it was the second-lowest-cost drug on its list.
Other companies have also been testing Sovaldi in the US.
There are more than 200,000 prescriptions for the drug in the United States, with more than 2 million written for the first six months of this year.
Some of those are given to patients with Crohn’s disease, a type of inflammatory bowel disease, which often affects the bowel.
But others are used for conditions such as ulcerative colitis and ulceration.
Sovaldi was developed in the UK and was tested on patients there.
The drugs were approved by the UK government in 2014 and 2015.
The price of the drug rose by $130 in the first half of this financial year.
That is despite the fact that there are no studies to show it is better than other treatments available.
A number of trials have shown that it is less expensive to treat patients with the disease.
But there is a big gap between the average price of one prescription and the cost of one treatment.
The average price for the Sovaldi drug is $130, but the cost for a single prescription is about $400.
The next-lowliest drug on this list is GSK’s Epidiolex, which costs about $300.
But because of the cost, it is not a drug to be taken every day.
And it does not appear to be working for patients with ulcerated colitis.
But a study published in the New England Journal of Medicine showed that EpidIOlex could be used for more than 30 per cent of patients.
It was given to 2,500 patients in a pilot study, and the average treatment cost was $150.
A study published last month in the journal Nature Medicine said that a single dose of Epidiopax was about 99 per cent effective in treating ulcerating colitis in people aged 50 and over.
But about 1,000 patients in the trial had been given only one dose.
The cost of Epi was about 15 per cent less than Sovaldi and GSK, but it cost about twice as much.
The costs of a single drug can be a factor in why patients decide to pay more.
But some researchers have argued that the cost is likely not a big reason why people choose to spend more on their prescription.
A 2010 study by a team of researchers at the University of Melbourne and the University at Buffalo looked at how people spend their money on drugs and concluded that the main reason was that they wanted to know if they were getting the best deal.
They used data from the Australian Bureau of Statistics to compare the average prices of drugs and their generic equivalents.
The researchers found that patients with an insurance policy with lower deductibles and coinsurance were more likely to pay higher prices for drugs.
The cheapest drugs were more expensive to administer than the cheapest generics, but patients with a higher deductible and coinsurances were more willing to pay for the best price.
They also reported that they were willing to spend less money on the generic equivalents of drugs.
There was a lot of variation in the prices of the cheapest drugs.
But patients who were on prescription-only plans were more reluctant to pay a higher price than those who were enrolled in a plan with a lower deductible and higher coinsurance.
In a separate study published earlier this year, a group of Australian researchers looked at the cost-effectiveness of different drugs.
They looked at three drugs that are in clinical trials: Epidium, a non-prescription drug, which treats the common flu virus, and Zidovudine, a generic drug.
Both of these drugs are used in the treatment of ulceratories.
The most expensive of these three drugs is called Zidavudine; the other two are Epidibenavir and Epidoprevir.
Both are prescribed for Crohns disease.
The authors said the cost per pill of Zidvudine was about three times that of Epidemium.
They concluded that Zidbemodine was “less effective” and that Epidemiothinum “was more effective”.
The cost per prescription of Zizdiben was about twice that of the other drugs in the study.
The report said